STOCK TITAN

Tenaya Therapeutics to Participate at the 35th Annual Piper Sandler Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Tenaya Therapeutics, Inc. (TNYA) CEO Faraz Ali to participate in 35th Annual Piper Sandler Healthcare Conference. Webcast available on company's website.
Positive
  • None.
Negative
  • None.

SOUTH SAN FRANCISCO, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Faraz Ali, Chief Executive Officer, will participate in the 35th Annual Piper Sandler Healthcare Conference taking place in New York, NY.

Details of participation are as follows:

Fireside Chat
Date: November 28, 2023
Time: 6:30 AM PT / 9:30 AM ET

A webcast of the Piper Sandler event will be available by visiting the Investors section of Tenaya’s website. A replay of the webcast will be available on the Tenaya website for approximately 30 days following the conference.

About Tenaya Therapeutics
Tenaya Therapeutics is a clinical-stage biotechnology company committed to a bold mission: to discover, develop and deliver potentially curative therapies that address the underlying drivers of heart disease. Leveraging its integrated and interrelated Gene Therapy, Cellular Regeneration and Precision Medicine platforms and proprietary core capabilities, the company is advancing a pipeline of novel therapies with diverse treatment modalities for rare genetic cardiovascular disorders and more prevalent heart conditions. Tenaya’s most advanced candidates include TN-201, a gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM), TN-401, a gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC), and TN-301, a small molecule HDAC6 inhibitor being initially developed for heart failure with preserved ejection fraction (HFpEF). Tenaya also has multiple early-stage programs progressing through preclinical development. For more information, visit www.tenayatherapeutics.com.

Contacts
Michelle Corral
VP, Corporate Communications and Investor Relations
IR@tenayathera.com

Investors
Julie Seidel
Stern Investor Relations
Julie.seidel@SternIR.com


The conference is scheduled for November 28, 2023.

The CEO will participate at 6:30 AM PT / 9:30 AM ET.

The webcast will be available on Tenaya's website in the Investors section.

The webcast will be available for approximately 30 days following the conference on the Tenaya website.
Tenaya Therapeutics Inc

NASDAQ:TNYA

TNYA Rankings

TNYA Latest News

TNYA Stock Data

Research and Development in Biotechnology
Professional, Scientific, and Technical Services

About TNYA

tenaya therapeutics is a privately-held biopharmaceutical company backed by the column group. the company was founded in 2016 by world-leading scientists from the gladstone institute’s cardiovascular division and the university of texas southwestern medical center. tenaya is dedicated to addressing heart failure through multipronged efforts that target the fundamental cellular pathologies present in diseased cardiac muscle and that leverage cutting-edge research in cardiac development and regeneration. tenaya has a lead gene therapy program focused on in vivo reprogramming of cardiac fibroblasts to cardiomyocytes to regenerate heart tissue, and additional programs focused on cardiomyopathies.